圣湘生物两款检测试剂获批上市

Core Viewpoint - Recently, Shengxiang Bio's self-developed drug genomic series products, including the human AGTR1 and CYP2C9 gene polymorphism nucleic acid testing kits (PCR-fluorescent probe method) and the human ADRB1 gene polymorphism nucleic acid testing kit (PCR-fluorescent probe method), have been approved for market launch by the National Medical Products Administration. This marks the 7th and 8th testing kits approved in Shengxiang Bio's pharmacogenetic testing product line, indicating the company's successful completion of a key segment in personalized medication guidance for hypertension [1]. Group 1 - Shengxiang Bio has developed two new gene testing kits that have received regulatory approval [1] - The newly approved products are part of a broader pharmacogenetic testing product line [1] - The approval signifies a strategic advancement in personalized medication for hypertension [1]